Bone Markers in Prostate Cancer Management
Author Information
Author(s): Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman R E, Delmas P D
Primary Institution: INSERM Research Unit 403, Hôpital E Herriot, Lyon, France
Hypothesis
The study aims to compare the clinical utility of new bone resorption markers to that of bone formation in patients with bone metastases from prostate cancer before and after bisphosphonate treatment.
Conclusion
Patients with prostate cancer and bone metastases show increased bone resorption that decreases after treatment with pamidronate.
Supporting Evidence
- Bone resorption markers were significantly higher in patients with prostate cancer and bone metastasis compared to other groups.
- After bisphosphonate treatment, bone resorption markers decreased significantly.
Takeaway
This study found that men with prostate cancer and bone metastases have higher levels of certain markers in their bones, and these levels go down after they receive treatment.
Methodology
The study assessed bone resorption and formation markers in patients with prostate cancer and bone metastases, comparing them to other groups before and after bisphosphonate treatment.
Participant Demographics
Thirty-nine patients with prostate cancer and bone metastasis, nine patients with prostate cancer without bone metastases, nine patients with benign prostatic hyperplasia, and 355 healthy age-matched men.
Statistical Information
P-Value
P = 0.001
Statistical Significance
p<0.006
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website